Drug name - Cubicin
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(5 years from now) | |
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(8 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 250MG/VIAL | POWDER;INTRAVENOUS | Discontinued |
| 500MG/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.